Independent register of U.S. FDA drug recalls · updated Oct 10, 2026
RxRecalls Get alerts
Class III · Low risk Terminated Initiated Jul 18, 2023 (3 years ago)

Dofetilide Capsules 500 mcg

Class III — Low risk. Unlikely to cause harm, but violates FDA regulations.

Why it was recalled

Out of Specification result observed in content uniformity testing

Cause type: Wrong potency / content

Sub- or super-potent product, or a failed content-uniformity / assay test. You may receive too little or too much active ingredient - a direct dosing risk. All wrong potency / content recalls.

What was recalled

Dofetilide Capsules 500 mcg (0.5mg), 60-count bottle, Rx Only, Manufactured by Sun Pharmaceutical Industries Limited, Survey No. 259/15, Dadra-396 191, (U.T of D & NH), India, Distributed by: Sun Pharmaceutical Industries, Inc. Cranbury, NJ 08512. NDC 47335-063-86

Affected NDC 47335-0063-86

Compare with the code on your package — it is the most precise check available.

Drug: Dofetilide

Product details

From the FDA NDC directory, for the product code this recall names. Compare with the label on your package.

ProductStrengthForm & routeLabelerType
Dofetilide
NDC 47335-0063
.5 mg/1 Capsule
Oral
Sun Pharmaceutical Industries, Inc. Rx
Recalling firm
Sun Pharmaceutical Industries INC
NDC code
47335-063-86
Origin
NJ, United States
Initiated by
Voluntary: Firm initiated
FDA recall number
D-1082-2023 · FDA notice

Low risk, still worth a check. Class III means the product is unlikely to cause harm but breaks an FDA rule (often labeling). If your lot matches, your pharmacy will normally swap it; there is no need for alarm. This recall is now terminated, which means the firm has finished removing the affected product; anything on pharmacy shelves today should be unaffected.

Other Dofetilide recalls

See all
Class II · Moderate risk

Dofetilide Capsules 500 mcg

CGMP Deviations: recalling drug products following an FDA inspection.

Terminated cGMP deviation Accord Healthcare, Inc. NDC 16729-492-12 D-0385-2023
Class II · Moderate risk

Dofetilide Capsules 250 mcg

CGMP Deviations: recalling drug products following an FDA inspection.

Terminated cGMP deviation Accord Healthcare, Inc. NDC 16729-491-12 D-0384-2023
Class II · Moderate risk

Dofetilide Capsules

CGMP Deviations: recalling drug products following an FDA inspection.

Terminated cGMP deviation Accord Healthcare, Inc. NDC 16729-490-12 D-0383-2023
Class II · Moderate risk

Tikosyn (dofetilide)

Failed Tablet/Capsule Specifications: Product being recalled due to the potential presence of cracked or broken capsules.

Terminated Failed specification Pfizer Inc. NDC 0069-5800-61 D-0292-2015

Other recalls by Sun Pharmaceutical Industries INC

All 2023 recalls
Class II · Moderate risk

Carbamazepine Tablets

CGMP Deviations; black spots found on tablets from burnt excipient during manufacturing

Ongoing cGMP deviation Sun Pharmaceutical Industries INC NDC 51672-4005-3 D-0770-2026
Class II · Moderate risk

Perampanel CIII Tablets

Labeling: Label Mix-up: 10mg Perampanel CIII tablet was found in a Perampanel CIII bottle labeled Perampanel 6 mg tablets.

Ongoing Labeling / mix-up Sun Pharmaceutical Industries INC NDC 51672-4206-6 D-0628-2026